Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Lei Lei Wu

News Reporter

Valora Therapeutics has $30 million to jump-start research on immunotherapies based on sugars — the kind that dots cell surfaces and helps devastating cancers evade immune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy